PET/CT in breast cancer: An update;Différents rôles de la TEP-TDM en sénologie: Mise au point

Bulletin du Cancer

Volumn 96, Issue 11, 2009, Pages 1053-1070

  Groheux, D ^a   Moretti, J L ^a   Giacchetti, S ^a   Hindie E ^a   Teyton, P ^a   Cuvier, C ^a   Bousquet, G ^a   Misset, J L ^a   Boin, C ^a   Espie M ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

18F FDG; Breast cancer; PET; PET CT; Recurrence; Staging

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; FLUORIDE SODIUM; FLUORODEOXYGLUCOSE F 18; THYMIDINE; 18 FLUORO 17 ESTRADIOL; 18-FLUORO-17-ESTRADIOL; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; BONE MATRIX; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; INTERNAL MAMMARY ARTERY; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SENSITIVITY ANALYSIS; SENTINEL LYMPH NODE BIOPSY; BREAST TUMOR; FEMALE; LYMPHADENECTOMY; METHODOLOGY; PAGET NIPPLE DISEASE; PATHOLOGY; SCINTISCANNING; TREATMENT OUTCOME; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DIDEOXYNUCLEOSIDES; ESTRADIOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODE EXCISION; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SODIUM FLUORIDE; TREATMENT OUTCOME;

EID: 73349105602     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0950     Document Type: Review

References (134)

1. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006 ; 33 : 254-62.
2. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007 ; 242 : 360-85.
3. Townsend D. Dual-modality-imaging: combining anatomy and function. J Nucl Med 2008 ; 49 : 938-55.
4. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993 ; 72 : 2979-85.
5. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002 ; 20 : 379-87.
6. Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL. Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res 1996 ; 56 : 2468-71.
7. Crippa F, Agresti R, Seregni E, Greco M, Pascali C, Bogni A, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998 ; 39 : 4-8.
8. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000 ; 18 : 3495-502.
9. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001 ; 42 : 9-16.
10. Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001 ; 28 : 351-8.
11. Buck A, Schirrmeister H, Kühn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002 ; 29 : 1317-23.
12. Gil-Rendo A, Martínez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F] fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 2009 ; 96 : 166-70.
13. Crowe Jr. JP, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994 ; 1 : 132-40.
14. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with (18F)2-deoxy-2-fluoro-d-glucose PET. Radiology 1993 ; 187 : 743-50.
15. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998 ; 25 : 1429-34.
16. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006 ; 98 : 267-74.
17. Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007 ; 73 : 1151-7.
18. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer 2007 ; 14 : 260-8.
19. Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 2008 ; 8 : 165.
20. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995 ; 36 : 1766-74.
21. Buck AK, Schirrmeister H, Mattfeldt T, Reske SN. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004 ; 31 : S80-7.
22. Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med 2007 ; 48 : 1266-72.
23. Overgaard J, Yilmaz M, Guldberg P, Hansen L, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 2000 ; 39 : 327-33.
24. Rudolph P, Alm P, Olsson H, Heidebrecht HJ, Fernö M, Baldetorp B, et al. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol 2001 ; 32 : 311-9.
25. Pinto AE, André S, Laranjeira C, Soares J. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology 2005 ; 37 : 45-50.
26. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor positive/progesterone receptor-positive/HER2 negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008 ; 112 : 995-1000.
27. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991 ; 179 : 765-70.
28. Scheidhauer K, Scharl A, Pietrzyk U, Wagner R, Gohring U, Schomacker K, et al. Qualitative18F-FDG PET in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996 ; 23 : 618-23.
29. Samson DJ, Flamm CR, Pisano ED, Aronson N. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy? Academic Radiology 2002 ; 9 : 773-83.
30. Walter C, Scheidhauer K, Scharl A, Goering UJ, Theissen P, Kugel H, et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol 2003 ; 13 : 1651-6.
31. Palmedo H, Bender H, Grünwald F, Mallmann P, Zamora P, Krebs D, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 1997 ; 24 : 1138-45.
32. Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman RE. Detection of primary breast carcinoma with a dedicated, largefield-of-view FDG PET mammography device: initial experience. Radiology 2005 ; 234 : 527-34.
33. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET. J Nucl Med 2005 ; 46 : 1819-24.
34. Mavi A, Urhan M, Yu JQ, Zhuang H, Houseni M, Cermik TF, et al. Dual-time-point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006 ; 47 : 1440-6.
35. Imbriaco M, Caprio MG, Limite G, Pace L, De Falco T, Capuano E, et al. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions. AJR Am J Roentgenol 2008 ; 191 : 1323-30.
36. Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E. Dualtime-point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer. Clin Radiol 2008 ; 63 : 1213-27.
37. Doshi NK, Shao Y, Silverman RW, Cherry SR. Design and evaluation of an LSO PET detector for breast cancer imaging. Med Phys 2000 ; 27 : 1535-43.
38. Tafra L. Positron emission tomography (PET) and mammography (PEM) for breast cancer: importance to surgeons. Ann Surg Oncol 2007 ; 14 : 3-13.
39. Raylman RR, Majewski S, Smith MF, Proffitt J, Hammond W, Srinivasan A, et al. The positron emission mammography/tomography breast imaging and biopsy system(PEM/PET): design, construction and phantom-based measurements. Phys Med Biol 2008 ; 53 : 637-53.
40. Murthy K, Aznar M, Thompson CJ, Loutfi A, Lisbona R, Gagnon JH. Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med 2000 ; 41 : 1851-8.
41. Berg WA, Weinberg IN, Narayanan D, Lobrano ME, Ross E, Amodei L, et al. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer. Breast J 2006 ; 12 : 309-23.
42. Tafra L, Cheng Z, Uddo J, Lobrano MB, Stein W, Berg WA, et al. Pilot clinical trial of 18F-fluorodeoxyglucose positron emission mammography in the surgical management of breast cancer. Am J Surg 2005 ; 190 : 628-32.
43. Bourguet P, Hitzel A, Houvenaeghel G, Vinatier D, Bosquet L, Bonichon F, et al. Bulletin de synthèse de veille 2005. Recommandations pour la pratique clinique : utilisation de la TEP-FDG dans les cancers du sein, de l'ovaire et de l'utérus. Bull Cancer 2006 ; 93 : 385-90.
44. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG, PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004 ; 22 : 277-85.
45. Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, et al. Selective sentinel node plus additional non-sentinel node biopsy based on an FDG PET/CT scan in early breast cancer patients: single institutional experience. World J Surg 2009 ; 33 : 943-9.
46. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002 ; 20 : 3628-36.
47. Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 2003 ; 10 : 622-7.
48. Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007 ; 18 : 473-8.
49. Zornoza G, Garcia-Velloso MJ, Sola J, Regueira FM, Pina L, Beorlegui C. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 2004 ; 30 : 15-9.
50. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med 1998 ; 28 : 290-302.
51. Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, et al. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001 ; 19 : 3516-23.
52. Danforth DN, Aloj L, Carrasquillo JA, Bacharach SL, Chow C, Zujewski J, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002 ; 75 : 135-46.
53. Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004 ; 27 : 407-10.
54. Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindié E, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008 ; 71 : 695-704.
55. Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008 ; 26 : 4746-51.
56. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, et al. Retrospective Study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009 ; 50 : 231-8.
57. Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, et al. Breast cancer staging in a single session: wholebody PET/CT mammography. J Nucl Med 2008 ; 49 : 1215-22.
58. Rousseau C, Bourbouloux E, Campion L, Fleury N, Bridji B, Chatal JF, et al. Brown fat in breast cancer patients: analysis of serial (18)F-FDG PET/CT scans. Eur J Nucl Med Mol Imaging 2006 ; 33 : 785-91.
59. Jacene HA, Goudarzi B, Wahl RL. Scalene muscle uptake: a potential pitfall in head and neck PET/CT. Eur J Nucl Med Mol Imaging 2008 ; 35 : 89-94.
60. Newman LA, Kuerer HM, Fornage B, Mirza N, Hunt KK, Ross MI, et al. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg 2001 ; 181 : 313-8.
61. Kuru B, Camlibel M, Dinc S, Gulcelik MA, Alagol H. Prognostic significance of axillary node and infraclavicular lymph node status after mastectomy. Eur J Surg Oncol 2003 ; 29 : 839-44.
62. Taghian A, Jagsi R, Makris A, Goldberg S, Ceilley E, Grignon L, et al. Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: practice is culture driven rather than evidence based. Int J Radiat Oncol Biol Phys 2004 ; 60 : 706-14.
63. Freedman GM, Fowble BL, Nicolaou N, Sigurdson ER, Torosian MH, Boraas MC, et al. Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist? Int J Radiat Oncol Biol Phys 2000 ; 46 : 805-14.
64. Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management: a systematic review. J Clin Oncol 2008 ; 26 : 4981-9.
65. Cermik TF, Mavi A, Basu S, Alavi A. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 2008 ; 35 : 475-83.
66. Landheer ML, Steffens MG, Klinkenbijl JH, Westenberg AH, Oyen WJ. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. Br J Surg 2005 ; 92 : 1363-7.
67. Port ER, Yeung H, Gonen M, Liberman L, Caravelli J, Borgen P, et al. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol 2006 ; 13 : 677-84.
68. Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 2008 ; 19 : 1249-54.
69. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008 ; 109 : 417-26.
70. Piperkova E, Raphael B, Altinyay ME, Castellon I, Libes R, Sandella N, et al. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management. Clin Nucl Med 2007 ; 32 : 429-34.
71. Abe K, Sasaki M, Kuwabara Y, Koga H, Baba S, Hayashi K, et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005 ; 19 : 573-9.
72. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005 ; 32 : 1253-8.
73. Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am 2007 ; 45 : 669-76.
74. Du Y, Cullum I, Illidge TM, Ell PJ. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007 ; 25 : 3440-7.
75. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007 ; 18 : 1927-34.
76. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000 ; 18 : 1676-88.
77. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000 ; 18 : 1689-95.
78. Kim SJ, Kim SK, Lee ES, Ro J, Kang S. Predictive value of [18F] FDG PET for pathological response of breast cancer to neoadjuvant chemotherapy. Ann Oncol 2004 ; 15 : 1352-7.
79. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006 ; 24 : 5366-72.
80. Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007 ; 34 : 1915-24.
81. McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007 ; 102 : 75-84.
82. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]Fluorodeoxyglucose. J Clin Oncol 2009 ; 27 : 535-41.
83. Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, et al. The role of (18)F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 2009 ; 19 : 1347-57.
84. Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, et al. (18)F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009 (sous presse).
85. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004 ; 231 : 305-32.
86. Moretti JL, Hindié E, Vercellino L. Therapeutic response evaluation by nuclear functional imaging. Bull Cancer 2007 ; 94 : F241-F2F4.
87. Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, Wong WL. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002 ; 38 : 375-9.
88. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur J Cancer 2009 ; 45 : 228-47.
89. Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 2006 ; 24 : 4587-93.
90. Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB, et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002 ; 9 : 913-21.
91. Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, et al. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 2007 ; 105 : 87-94.
92. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008 ; 247 : 189-96.
93. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005 ; 46 : 1144-50.
94. Couturier O, Jerusalem G, N'Guyen JM, Hustinx R. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 2006 ; 12 : 6437-43.
95. Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 2005 ; 23 : 1664-73.
96. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999 ; 26 : 51-6.
97. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001 ; 19 : 2797-803.
98. Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M, Katzenellenbogen JA, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor- positive breast cancer. Breast Cancer Res Treat 2009 ; 113 : 509-17.
99. Grahek D, Montravers F, Kerrou K, Aide N, Lotz JP, Talbot JN. [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging 2004 ; 31 : 179-88.
100. Eubank WB. Diagnosis of recurrent and metastatic disease using F-18 fluorodeoxyglucose-positron emission tomography in breast cancer. Radiol Clin North Am 2007 ; 45 : 659-67.
101. Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, et al. F-18 fluorodeoxyglucose positron emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003 ; 38 : 250-6.
102. Veit-Haibach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EA, et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 2007 ; 80 : 508-15.
103. Dirisamer A, Halpern BS, Flöry D, Wolf F, Beheshti M, Mayerhoefer ME, et al. Integrated contrast-enhanced diagnostic wholebody PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol 2009 (sous presse).
104. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDGPET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005 ; 90 : 105-12.
105. Schmidt GP, Baur-Melnyk A, Haug A, Heinemann V, Bauerfeind I, Reiser MF, et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol 2008 ; 65 : 47-58.
106. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007 ; 27 : S215-S29.
107. Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004 ; 183 : 479-86.
108. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008 ; 49 : 480-508.
109. Emmering J, Krak NC, Van der Hoeven JJ, Spreeuwenberg MD, Twisk JW, Meijer S, et al. Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology. Ann Oncol 2008 ; 19 : 1573-7.
110. Cachin F, Prince HM, Hogg A, Ware RE, Hicks RJ. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 2006 ; 24 : 3026-31.
111. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, et al. Optimizing radiolabeled engineered antip185HER2 antibody fragments for in vivo imaging. Cancer Res 2005 ; 65 : 5907-16.
112. Yagle KJ, Eary JF, Tait JF, Grierson JR, Link JM, Lewellen B, et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005 ; 46 : 658-66.
113. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002 ; 43 : 1210-7.
114. Kumar R, Dhanpathi H, Basu S, Rubello D, Fanti S, Alavi A. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging. Q J Nucl Med Mol Imaging 2008 ; 52 : 50-65.
115. Couturier O, Leost F, Campone M, Carlier T, Chatal JF, Hustinx R. Is 3′OElig;-deoxy-3′OElig;- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG? Bull Cancer 2005 ; 92 : 789-98.
116. Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla HJ, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004 ; 31 : 720-4.
117. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998 ; 4 : 1334-6.
118. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 3′OElig;-[F-18]fluoro-3′OElig;-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006 ; 8 : 36-42.
119. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at a week post-chemotherapy: a pilot study in breast cancer patients with 3′OElig;-deoxy-3′OElig;-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007 ; 34 : 1339-47.
120. Direcks WG, Berndsen SC, Proost N, Peters GJ, Balzarini J, Spreeuwenberg MD, et al. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer 2008 ; 99 : 481-7.
121. Dittmann H, Jusufoska A, Dohmen BM, Smyczek-Gargya B, Fersis N, Pritzkow M, et al. 3′OElig;-Deoxy 3′OElig;[(18)F] fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliferation after doxorubicin and docetaxel treatment. Nucl Med Biol 2009 ; 36 : 163-9.
122. Kumar R. Targeted functional imaging in breast cancer. Eur J Nucl Med Mol Imaging 2007 ; 34 : 346-53.
123. Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, et al. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res 1997 ; 57 : 3723-7.
124. Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988 ; 169 : 45-8.
125. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995 ; 36 : 1766-74.
126. Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. J Nucl Med 2008 ; 49 (Suppl 2) : 149S-163S.
127. Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008 ; 49 : 367-74.
128. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006 ; 24 : 2793-9.
129. Cook GJ, Fogelman I. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med 2001 ; 45 : 47-52.
130. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004 ; 22 : 2942-53.
131. Hawkins RA, Choi Y, Huang SC, Hoh CK, Dahlbom M, Schiepers C, et al. Evaluation of the skeletal kinetics of fluorine-18- fluoride ion with PET. J Nucl Med 1992 ; 33 : 633-42.
132. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008 ; 49 : 68-78.
133. Petrén-Mallmin M, Andréasson I, Ljunggren O, Ahlström H, Bergh J, Antoni G, et al. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol 1998 ; 27 : 72-6.
134. Wade AA, Scott JA, Kuter I, Fischman AJ. Flare response in 18F-fluoride ion PET bone scanning. AJR 2006 ; 186 : 1783-6.